Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T94033
(Former ID: TTDS00202)
|
|||||
Target Name |
Coagulation factor IIa (F2)
|
|||||
Synonyms |
Prothrombin; Coagulation factor II
Click to Show/Hide
|
|||||
Gene Name |
F2
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 8 Target-related Diseases | + | ||||
1 | Bleeding disorder [ICD-11: GA20-GA21] | |||||
2 | Coagulation defect [ICD-11: 3B10] | |||||
3 | Ischaemic/haemorrhagic stroke [ICD-11: 8B20] | |||||
4 | Multiple sclerosis [ICD-11: 8A40] | |||||
5 | Myocardial infarction [ICD-11: BA41-BA43] | |||||
6 | Nutritional deficiency [ICD-11: 5B50-5B71] | |||||
7 | Thrombocytopenia [ICD-11: 3B64] | |||||
8 | Thrombosis [ICD-11: DB61-GB90] | |||||
Function |
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Click to Show/Hide
|
|||||
BioChemical Class |
Peptidase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.4.21.5
|
|||||
Sequence |
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY GFYTHVFRLKKWIQKVIDQFGE Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
ADReCS ID | BADD_A04982 | |||||
HIT2.0 ID | T19CUN |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 10 Approved Drugs | + | ||||
1 | Anisindione | Drug Info | Approved | Coagulation defect | [2], [3] | |
2 | Argatroban | Drug Info | Approved | Thrombosis | [4], [5] | |
3 | ATryn antithrombin | Drug Info | Approved | Multiple sclerosis | [6] | |
4 | Bivalirudin | Drug Info | Approved | Thrombocytopenia | [5], [7] | |
5 | Dabigatran | Drug Info | Approved | Stroke | [8], [9] | |
6 | Desirudin Recombinant | Drug Info | Approved | Coagulation defect | [10] | |
7 | Human prothrombin complex concentrate | Drug Info | Approved | Bleeding disorder | [10] | |
8 | Lepirudin | Drug Info | Approved | Thrombocytopenia | [5], [11] | |
9 | Pyridoxal Phosphate | Drug Info | Approved | Malnutrition | [12], [13] | |
10 | Ximelegatran | Drug Info | Approved | Myocardial infarction | [1] | |
Clinical Trial Drug(s) | [+] 13 Clinical Trial Drugs | + | ||||
1 | EFEGATRAN SULFATE HYDRATE | Drug Info | Phase 2 | Myocardial infarction | [16] | |
2 | LB-30870 | Drug Info | Phase 2 | Myocardial infarction | [17] | |
3 | NU-172 | Drug Info | Phase 2 | Thrombosis | [18] | |
4 | Odiparcil | Drug Info | Phase 2 | Cardiovascular disease | [19] | |
5 | Pegmusirudin | Drug Info | Phase 2 | Angina pectoris | [20] | |
6 | Recombinant RGD-hirudin | Drug Info | Phase 2 | Thrombosis | [21] | |
7 | TF0023 | Drug Info | Phase 2 | Heart attack | [22] | |
8 | AZD-8165 | Drug Info | Phase 1 | Thrombosis | [23], [24] | |
9 | DP-4088 | Drug Info | Phase 1 | Coagulation defect | [25] | |
10 | EP-42675 | Drug Info | Phase 1 | Thrombosis | [26] | |
11 | RWJ-671818 | Drug Info | Phase 1 | Thrombosis | [27] | |
12 | Solulin | Drug Info | Phase 1 | Thrombosis | [28] | |
13 | SSR-128428 | Drug Info | Phase 1 | Thrombosis | [29] | |
Discontinued Drug(s) | [+] 22 Discontinued Drugs | + | ||||
1 | Ximelagatran | Drug Info | Withdrawn from market | Coagulation defect | [5], [30] | |
2 | AZD0837 | Drug Info | Discontinued in Phase 2 | Thrombosis | [31], [32] | |
3 | Dermolastin | Drug Info | Discontinued in Phase 2 | Atopic dermatitis | [33] | |
4 | INOGATRAN | Drug Info | Discontinued in Phase 2 | Myocardial infarction | [34] | |
5 | Napsagatran | Drug Info | Discontinued in Phase 2 | Myocardial infarction | [35] | |
6 | SSR-182289 | Drug Info | Discontinued in Phase 2 | Myocardial infarction | [36] | |
7 | Vasoflux | Drug Info | Discontinued in Phase 2 | Myocardial infarction | [37] | |
8 | BCX-1470 | Drug Info | Discontinued in Phase 1 | Bleeding disorder | [40] | |
9 | CJC-1004 | Drug Info | Discontinued in Phase 1 | Thrombosis | [41] | |
10 | CVS-1123 | Drug Info | Discontinued in Phase 1 | Myocardial infarction | [42] | |
11 | GW-473178 | Drug Info | Discontinued in Phase 1 | Heart arrhythmia | [43] | |
12 | Licostinel | Drug Info | Discontinued in Phase 1 | Neurological disorder | [44] | |
13 | S-18326 | Drug Info | Discontinued in Phase 1 | Myocardial infarction | [45] | |
14 | UK-156406 | Drug Info | Discontinued in Phase 1 | Myocardial infarction | [46] | |
15 | BCH-2763 | Drug Info | Terminated | Thrombosis | [49] | |
16 | BMS-189664 | Drug Info | Terminated | Myocardial infarction | [50] | |
17 | CVS-995 | Drug Info | Terminated | Myocardial infarction | [51] | |
18 | GS-522 | Drug Info | Terminated | Thrombosis | [52] | |
19 | L-373890 | Drug Info | Terminated | Thrombosis | [53] | |
20 | L-374,087 | Drug Info | Terminated | Thrombosis | [54] | |
21 | Org-34092 | Drug Info | Terminated | Thrombosis | [55] | |
22 | SR-80027A | Drug Info | Terminated | Thrombosis | [56] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Modulator | [+] 15 Modulator drugs | + | ||||
1 | Anisindione | Drug Info | [57] | |||
2 | ATryn antithrombin | Drug Info | [61] | |||
3 | Desirudin Recombinant | Drug Info | [64] | |||
4 | Human prothrombin complex concentrate | Drug Info | [65] | |||
5 | Pegmusirudin | Drug Info | [65] | |||
6 | Recombinant RGD-hirudin | Drug Info | [72] | |||
7 | EP-42675 | Drug Info | [74] | |||
8 | RWJ-671818 | Drug Info | [27] | |||
9 | Solulin | Drug Info | [28] | |||
10 | SSR-128428 | Drug Info | [75] | |||
11 | INOGATRAN | Drug Info | [82] | |||
12 | bufrudin | Drug Info | [108], [109] | |||
13 | TB-101 | Drug Info | [65] | |||
14 | TB-102 | Drug Info | [65] | |||
15 | Tumor vascular thrombogen | Drug Info | [65] | |||
Inhibitor | [+] 112 Inhibitor drugs | + | ||||
1 | Argatroban | Drug Info | [58], [59], [60] | |||
2 | Bivalirudin | Drug Info | [59], [62], [63] | |||
3 | Dabigatran | Drug Info | [9] | |||
4 | Lepirudin | Drug Info | [66] | |||
5 | Pyridoxal Phosphate | Drug Info | [63] | |||
6 | Ximelegatran | Drug Info | [1] | |||
7 | Hirudin | Drug Info | [59], [62], [67] | |||
8 | MELAGATRAN | Drug Info | [68] | |||
9 | EFEGATRAN SULFATE HYDRATE | Drug Info | [10] | |||
10 | LB-30870 | Drug Info | [10] | |||
11 | NU-172 | Drug Info | [69], [70] | |||
12 | Odiparcil | Drug Info | [71] | |||
13 | TF0023 | Drug Info | [73] | |||
14 | AZD-8165 | Drug Info | [65] | |||
15 | DP-4088 | Drug Info | [65] | |||
16 | Ximelagatran | Drug Info | [76], [59] | |||
17 | AZD0837 | Drug Info | [77] | |||
18 | Dermolastin | Drug Info | [78], [79], [80], [81] | |||
19 | Napsagatran | Drug Info | [83] | |||
20 | SSR-182289 | Drug Info | [10] | |||
21 | Vasoflux | Drug Info | [84] | |||
22 | BCX-1470 | Drug Info | [85] | |||
23 | CJC-1004 | Drug Info | [86] | |||
24 | CVS-1123 | Drug Info | [87] | |||
25 | GW-473178 | Drug Info | [88] | |||
26 | Licostinel | Drug Info | [89] | |||
27 | S-18326 | Drug Info | [10] | |||
28 | UK-156406 | Drug Info | [10] | |||
29 | BCH-2763 | Drug Info | [90] | |||
30 | BMS-189664 | Drug Info | [10] | |||
31 | CVS-995 | Drug Info | [91] | |||
32 | Efegatran | Drug Info | [92] | |||
33 | GS-522 | Drug Info | [93] | |||
34 | L-373890 | Drug Info | [94] | |||
35 | L-374,087 | Drug Info | [95] | |||
36 | LB30057 | Drug Info | [96] | |||
37 | Org-34092 | Drug Info | [65] | |||
38 | PPACK | Drug Info | [92] | |||
39 | SR-80027A | Drug Info | [97] | |||
40 | (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone | Drug Info | [98] | |||
41 | (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone | Drug Info | [98] | |||
42 | (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone | Drug Info | [98] | |||
43 | (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone | Drug Info | [98] | |||
44 | (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone | Drug Info | [98] | |||
45 | 1,2,3,4,6-penta-O-galloyl-beta-D-glucose | Drug Info | [99] | |||
46 | 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE | Drug Info | [100] | |||
47 | 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide | Drug Info | [98] | |||
48 | 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine | Drug Info | [101] | |||
49 | 2-NAPHTHALENESULFONIC ACID | Drug Info | [100] | |||
50 | 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine | Drug Info | [102] | |||
51 | 3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate | Drug Info | [103] | |||
52 | 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL | Drug Info | [100] | |||
53 | 4-(3,4-Diethoxy-benzylamino)-benzamidine | Drug Info | [104] | |||
54 | 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine | Drug Info | [104] | |||
55 | 4-hydroxyphenylpyruvic acid | Drug Info | [100] | |||
56 | 4-iodobenzo[b]thiophene 2-carboxamidine | Drug Info | [100] | |||
57 | 4-TERT-BUTYLBENZENESULFONIC ACID | Drug Info | [100] | |||
58 | 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE | Drug Info | [100] | |||
59 | 5-desgalloylstachyurin | Drug Info | [99] | |||
60 | 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE | Drug Info | [100] | |||
61 | AC-(D)PHE-PRO-BOROHOMOLYS-OH | Drug Info | [100] | |||
62 | AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH | Drug Info | [100] | |||
63 | AC-(D)PHE-PRO-BOROLYS-OH | Drug Info | [100] | |||
64 | Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir | Drug Info | [105] | |||
65 | Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir | Drug Info | [105] | |||
66 | Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir | Drug Info | [105] | |||
67 | Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir | Drug Info | [105] | |||
68 | Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir | Drug Info | [105] | |||
69 | Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir | Drug Info | [105] | |||
70 | Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir | Drug Info | [105] | |||
71 | Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir | Drug Info | [105] | |||
72 | Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir | Drug Info | [105] | |||
73 | BENZOTHIAZOLE | Drug Info | [100] | |||
74 | Beta-(2-Naphthyl)-Alanine | Drug Info | [100] | |||
75 | Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide | Drug Info | [100] | |||
76 | BMS-344577 | Drug Info | [106] | |||
77 | BMS-740808 | Drug Info | [107] | |||
78 | CASUARIIN | Drug Info | [99] | |||
79 | CHLORODYSINOSIN A | Drug Info | [110] | |||
80 | CRA_8696 | Drug Info | [100] | |||
81 | Cyclotheonamide E | Drug Info | [111] | |||
82 | Cyclotheonamide E4 | Drug Info | [111] | |||
83 | Cyclotheonamide E5 | Drug Info | [111] | |||
84 | D-leucyl-N-(3-chlorobenzyl)-L-prolinamide | Drug Info | [100] | |||
85 | D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | Drug Info | [100] | |||
86 | D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide | Drug Info | [100] | |||
87 | D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide | Drug Info | [100] | |||
88 | D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide | Drug Info | [100] | |||
89 | D-phenylalanyl-N-benzyl-L-prolinamide | Drug Info | [100] | |||
90 | D-Pro-Phe-Arg chloromethyl ketone | Drug Info | [112] | |||
91 | Desirudine | Drug Info | [63] | |||
92 | Enoxaprin | Drug Info | [113] | |||
93 | Gamma-Carboxy-Glutamic Acid | Drug Info | [114] | |||
94 | GR-133686 | Drug Info | [115] | |||
95 | Haempatch | Drug Info | [65] | |||
96 | Hemi-Babim | Drug Info | [100] | |||
97 | Heparin-Cantithrombin III | Drug Info | [116] | |||
98 | L-370,518 | Drug Info | [62] | |||
99 | L-375378 | Drug Info | [117] | |||
100 | LB30812 | Drug Info | [118] | |||
101 | Lysophosphotidylserine | Drug Info | [114] | |||
102 | Macrocyclic tripeptide motif | Drug Info | [119] | |||
103 | Melogatran | Drug Info | [116] | |||
104 | Methyl L-phenylalaninate | Drug Info | [100] | |||
105 | METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE | Drug Info | [100] | |||
106 | N4-(N,N-diphenylcarbamoyl)-aminoguanidine | Drug Info | [100] | |||
107 | OSCILLARIN | Drug Info | [110] | |||
108 | RAZAXABAN | Drug Info | [120] | |||
109 | RWJ-50353 | Drug Info | [121] | |||
110 | S-2238 | Drug Info | [122] | |||
111 | Tellimagrandin II | Drug Info | [99] | |||
112 | VE-04051645 | Drug Info | [65] | |||
Cofactor | [+] 1 Cofactor drugs | + | ||||
1 | Vitamin K | Drug Info | [123] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Proflavine | Ligand Info | |||||
Structure Description | ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN | PDB:1BCU | ||||
Method | X-ray diffraction | Resolution | 2.00 Å | Mutation | No | [124] |
PDB Sequence |
IVEGSDAEIG
25 MSPWQVMLFR35 KSPQELLCGA44 SLISDRWVLT54 AAHCLLYPPW60D DKNFTENDLL 65 VRIGKHSRTR75 YERNIEKISM84 LEKIYIHPRY94 NWRENLDRDI103 ALMKLKKPVA 113 FSDYIHPVCL123 PDRETAASLL130 QAGYKGRVTG140 WGNLKEGQPS153 VLQVVNLPIV 163 ERPVCKDSTR173 IRITDNMFCA183 GYKPDEGKRG188 DACEGDSGGP198 FVMKSPFNNR 206 WYQMGIVSWG216 EGCDRDGKYG226 FYTHVFRLKK236 WIQKVIDQF
|
|||||
|
||||||
Ligand Name: Melagatran | Ligand Info | |||||
Structure Description | HUMAN THROMBIN-INHIBITOR COMPLEX | PDB:1K22 | ||||
Method | X-ray diffraction | Resolution | 1.93 Å | Mutation | No | [125] |
PDB Sequence |
IVEGSDAEIG
25 MSPWQVMLFR35 KSPQELLCGA44 SLISDRWVLT54 AAHCLLYPPW60D DKNFTENDLL 65 VRIGKHSRTR75 YERNIEKISM84 LEKIYIHPRY94 NWRENLDRDI103 ALMKLKKPVA 113 FSDYIHPVCL123 PDRETAASLL130 QAGYKGRVTG140 WGNLKETGQP152 SVLQVVNLPI 162 VERPVCKDST172 RIRITDNMFC182 AGYKPDEGKR187 GDACEGDSGG197 PFVMKSPFNN 205 RWYQMGIVSW215 GEGCDRDGKY225 GFYTHVFRLK235 KWIQKVIDQF245 G |
|||||
|
HIS57
3.403
TYR60A
3.475
TRP60D
3.000
GLU97A
3.840
ASN98
4.273
LEU99
3.682
ILE174
3.540
ASP189
2.734
ALA190
3.130
CYS191
3.871
GLU192
3.903
GLY193
4.992
|
|||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Phospholipase D signaling pathway | hsa04072 | Affiliated Target |
|
Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
Neuroactive ligand-receptor interaction | hsa04080 | Affiliated Target |
|
Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
Complement and coagulation cascades | hsa04610 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
Platelet activation | hsa04611 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
Regulation of actin cytoskeleton | hsa04810 | Affiliated Target |
|
Class: Cellular Processes => Cell motility | Pathway Hierarchy |
Degree | 31 | Degree centrality | 3.33E-03 | Betweenness centrality | 2.00E-03 |
---|---|---|---|---|---|
Closeness centrality | 2.08E-01 | Radiality | 1.36E+01 | Clustering coefficient | 1.12E-01 |
Neighborhood connectivity | 8.39E+00 | Topological coefficient | 6.61E-02 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6960). | |||||
REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010909. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6385). | |||||
REF 5 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 6 | Clinical pipeline report, company report or official report of Revo biologics. | |||||
REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470). | |||||
REF 8 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6380). | |||||
REF 9 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||||
REF 10 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6469). | |||||
REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5249). | |||||
REF 13 | Drug information of Pyridoxal Phosphate, 2008. eduDrugs. | |||||
REF 14 | ClinicalTrials.gov (NCT00338897) Dose Ranging Study in Elective Total Hip Replacement Surgery. U.S. National Institutes of Health. | |||||
REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033781) | |||||
REF 16 | Efegatran. Institute for drug research/IVAX. IDrugs. 2001 Jun;4(6):691-4. | |||||
REF 17 | Frontiers in Anti-Infective Drug Discovery, Atta-ur-Rahman, . Iqbal Choudhary. Page(57). | |||||
REF 18 | ClinicalTrials.gov (NCT00808964) Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery. U.S. National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT00240643) Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke. U.S. National Institutes of Health. | |||||
REF 20 | ClinicalTrials.gov (NCT00074620) A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis. U.S. National Institutes of Health. | |||||
REF 21 | The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Thromb Res. 2010 Oct;126(4):e339-43. | |||||
REF 22 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 23 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7727). | |||||
REF 24 | ClinicalTrials.gov (NCT01150812) Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects. U.S. National Institutes of Health. | |||||
REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028740) | |||||
REF 26 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023539) | |||||
REF 27 | Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RW... J Med Chem. 2010 Feb 25;53(4):1843-56. | |||||
REF 28 | The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82. | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020651) | |||||
REF 30 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6381). | |||||
REF 31 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7682). | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018351) | |||||
REF 33 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018071) | |||||
REF 34 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005012) | |||||
REF 35 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004026) | |||||
REF 36 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015478) | |||||
REF 37 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007938) | |||||
REF 38 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023381) | |||||
REF 39 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019755) | |||||
REF 40 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009938) | |||||
REF 41 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014574) | |||||
REF 42 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004614) | |||||
REF 43 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039) | |||||
REF 44 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003616) | |||||
REF 45 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004736) | |||||
REF 46 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010067) | |||||
REF 47 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005051) | |||||
REF 48 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001867) | |||||
REF 49 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007017) | |||||
REF 50 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010403) | |||||
REF 51 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004615) | |||||
REF 52 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003259) | |||||
REF 53 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009558) | |||||
REF 54 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009151) | |||||
REF 55 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010730) | |||||
REF 56 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005178) | |||||
REF 57 | Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. | |||||
REF 58 | Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44. | |||||
REF 59 | New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8. | |||||
REF 60 | Enzyme-controlling medicines: introduction. Semin Thromb Hemost. 1997;23(6):493-501. | |||||
REF 61 | Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779. | |||||
REF 62 | Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 1998 Mar;79(3):656-62. | |||||
REF 63 | New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32. | |||||
REF 64 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 65 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). | |||||
REF 66 | Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50. | |||||
REF 67 | Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69. | |||||
REF 68 | Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. | |||||
REF 69 | Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214. | |||||
REF 70 | Aptamers in Bioanalysis. M. Mascini. 2009. Wiley. Page(46). | |||||
REF 71 | A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. | |||||
REF 72 | The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8. | |||||
REF 73 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 74 | EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33. | |||||
REF 75 | Company report (Sanofi) (drug: FY2008) | |||||
REF 76 | Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol In Vitro. 2009 Oct;23(7):1305-10. | |||||
REF 77 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||||
REF 78 | Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009. | |||||
REF 79 | rAAt (inhaled) Arriva/Hyland Immuno. Curr Opin Mol Ther. 2006 Feb;8(1):76-82. | |||||
REF 80 | Optimization of the bioprocessing conditions for scale-up of transient production of a heterologous protein in plants using a chemically inducible viral amplicon expression system. Biotechnol Prog. 2009 May-Jun;25(3):722-34. | |||||
REF 81 | Bioreactor strategies for improving production yield and functionality of a recombinant human protein in transgenic tobacco cell cultures. Biotechnol Bioeng. 2009 Feb 1;102(2):508-20. | |||||
REF 82 | Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther. 1996 Jun;277(3):1276-83. | |||||
REF 83 | Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8. | |||||
REF 84 | Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 1999 Feb 9;99(5):682-9. | |||||
REF 85 | Recent Developments in Low Molecular Weight Complement Inhibitors. Mol Immunol. 2009 December; 47(2-3): 185-195. | |||||
REF 86 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408. | |||||
REF 87 | CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol. 1997 Feb;29(2):240-9. | |||||
REF 88 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039) | |||||
REF 89 | Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. | |||||
REF 90 | BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 1998 Feb;79(2):431-8. | |||||
REF 91 | Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic. Protein Sci. 1996 Mar;5(3):422-33. | |||||
REF 92 | Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204. | |||||
REF 93 | A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum. Pharm Res. 1995 Dec;12(12):1937-42. | |||||
REF 94 | L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett. 1998 Apr 7;8(7):817-22. | |||||
REF 95 | Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21. | |||||
REF 96 | Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. Thromb Haemost. 2003 Jan;89(1):104-11. | |||||
REF 97 | Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood. 1994 Oct 15;84(8):2571-7. | |||||
REF 98 | N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. | |||||
REF 99 | Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. | |||||
REF 100 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 101 | Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. | |||||
REF 102 | Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. | |||||
REF 103 | 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603. | |||||
REF 104 | Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. | |||||
REF 105 | Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. | |||||
REF 106 | Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. | |||||
REF 107 | Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett. 2008 Jan 15;18(2):749-54. | |||||
REF 108 | Leech therapeutic applications.Indian J Pharm Sci.2013 Mar;75(2):127-37. | |||||
REF 109 | Isolation of thrombin inhibitor from the leech Hirudinaria manillensis. Blood Coagul Fibrinolysis. 1991 Feb;2(1):83-9. | |||||
REF 110 | From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32. | |||||
REF 111 | Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61. | |||||
REF 112 | Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80. | |||||
REF 113 | Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv. 1994 Jun;49(6):424-31. | |||||
REF 114 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 115 | 5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60. | |||||
REF 116 | Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4. | |||||
REF 117 | Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4. | |||||
REF 118 | Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. J Med Chem. 2003 Aug 14;46(17):3612-22. | |||||
REF 119 | Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996). | |||||
REF 120 | Phenyltriazolinones as potent factor Xa inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1373-7. | |||||
REF 121 | Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. | |||||
REF 122 | Screening for selective thrombin inhibitors in mushrooms. Blood Coagul Fibrinolysis. 2001 Mar;12(2):123-8. | |||||
REF 123 | Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy. Tohoku J Exp Med. 1986 Aug;149(4):351-7. | |||||
REF 124 | X-ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human alpha-thrombin. FEBS Lett. 1998 Mar 27;425(2):229-33. | |||||
REF 125 | Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J Mol Biol. 2001 Oct 26;313(3):593-614. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.